ClinicalTrials.gg
CompletedNCT04156620Updated Jun 18, 2024Results posted

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

A Phase 3 interventional study of Secukinumab and Placebo in Ankylosing Spondylitis, sponsored by Novartis Pharmaceuticals. Completed at 103 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
527
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing secukinumab in Spondylitis, Ankylosing — 3 open to participants now, 4 under way, none of them phase 3. secukinumab · Spondylitis, Ankylosing.

Enrollment
3rd of 20
527 · median 223
Started
2019
with 1 other
Phase 3
11 of 20
none open now
Registered
16th of 20
by date
Lead sponsor
15 of 20
Novartis Pharmaceuticals

Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 11 in phase 3, and was the 16th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

3 of the 20 studies testing secukinumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing secukinumab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

The purpose of this global study was to demonstrate the efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in participants with active ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA ) at Week 16 despite current or previous non-steroidal anti inflammatory drugs (NSAID), disease-modifying antirheumatic drugs (DMARD) and/or anti Tumor Necrosis Factor (TNF) therapy. In addition, to further support efficacy and safety of an i.v. regimen, data was collected for up to 52 weeks of treatment.

Read the detailed description

This multicenter study used a randomized, double-blind, placebo-controlled, parallel-group design to study the efficacy, safety, and tolerability of treatment with intravenous secukinumab (initial dose of 6 mg/kg followed thereafter with 3 mg/kg administered every four weeks starting at Week 4) in subjects with active axial spondyloarthritis (axSpA). The study population consisted of active of 413 participants with AS and 113 participants with active nr-axSpA.

This study consisted of 4 periods totaling up to 70 weeks: the screening period (up to 10 weeks), the treatment period 1 (total duration of 16 weeks), treatment period 2 (total duration of 36 weeks) followed by the safety follow up period of 8 weeks after the end of treatment visit (at Week 60) regardless of whether participant completed the study as planned or discontinued prematurely.

At baseline, participants were randomized to one of the two treatment groups and stratified to disease condition (AS or nr-axSPa):

  • Group 1: secukinumab 6 mg/kg i.v.) at baseline and which was followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52) at clinic visits
  • Group 2: i.v. placebo at baseline, Weeks 4, 8, and 12 and switched to secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52) at clinic visits

Although study treatment was open label secukinumab i.v. starting at Week 16, all subjects and investigators/site staff remained blinded to original treatment assignment to ensure unbiased efficacy and safety assessments for the remainder of the study. This study enrolled participants with active disease despite current or previous NSAIDs, conventional DMARDs and/or TNF inhibitor therapy or intolerance to these therapies. The regular assessment of disease activity ensured that subjects who experienced worsening of disease in any of the treatment groups could exit the study at any time upon their own accord or based on the advice of the investigator.

A temporary pause of study recruitment only was implemented from 09-Apr-2020 to 11-May-2020, due to the COVID-19 pandemic, but not for study visits, assessments or other conduct of the study.

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • Active axSpA
  • Axial spondyloarthritis
  • non-radiographic-axSpA
  • nr-axSpA
  • ankylosing spondylitis
  • AS
  • inflammatory back pain
  • sacroiliitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for inclusion in this study must meet all of the following criteria:

  1. Subject must be able to understand and communicate with the investigator, comply with the requirements of the study. and must give written, signed and dated before any study assessment is performed
  2. Male and non-pregnant, non-lactating female patients ≥ 18 years of age
  3. Diagnosis of axSpA according to ASAS criteria

    1. Inflammatory back pain for at least 6 months
    2. Onset before 45 years of age
  4. For subjects with AS: Diagnosis of AS with prior documented radiologic evidence (x-ray or radiologist's report) fulfilling the Modified New York criteria for AS
  5. For subjects with nr-axSpA:

    X-ray of SIJ negative (centrally read) for AS by Modified NY criteria AND

    1. Sacroiliitis on MRI (centrally read) with ≥ 1 SpA feature OR HLA-B-27 positive with ≥2 SpA features AND
    2. Objective signs of inflammation at screening, evident by either MRI with SIJ inflammation (centrally read) AND / OR hsCRP > (as defined by the central lab)
  6. Active axial SpA assessed by BASDAI ≥4 cm (0-10 cm) at Baseline
  7. Spinal pain as measured by BASDAI question #2 ≥ 4 cm (0-10 cm) at Baseline
  8. Total back pain as measured by VAS ≥ 40 mm (0-100 mm) at Baseline
  9. Subjects should have had inadequate response or failure to respond to at least 2 NSAIDs at an approved dose for a minimum of 4 weeks in total and a minimum of 2 weeks for each NSAID prior to randomization, or less than 4 weeks if therapy had to be withdrawn due to intolerance, toxicity or
  10. Subjects who are regularly taking NSAIDs (including COX-1 or COX-2 inhibitors) as part of their AS or nr-axSpA therapy are required to be on a stable dose for at least 2 weeks before randomization
  11. Subjects who are intolerant or have been inadequate responders to a TNF inhibitor (not more than one) will be allowed to enter into the study (not more than 20% per group). They must have experienced an inadequate response to previous or current treatment at an approved dose for at least 3 months prior to randomization, or have been intolerant to at least one administration of an anti-TNF agent. These subjects will undergo an appropriate prior to randomization, if required

    1. 4 weeks for Enbrel® (etanercept) - with a terminal half-life of 102 ± 30 hours
    2. 8 weeks for Remicade® (infliximab) - with a terminal half-life of 8.0-9.5 days
    3. 10 weeks for Humira® (adalimumab) - with a terminal half-life of 10-20 days (average 2 weeks)
    4. 10 weeks for Simponi® (golimumab) - with a terminal half-life of 11-14 days
    5. 10 weeks for Cimzia® (certolizumab) - with a terminal half-life of 14 days
  12. Subjects taking methotrexate (MTX) (≤ 25 mg/week ) or sulfasalazine (≤ 3 g/day) are allowed to continue their medication and must have taken it for at least 3 months and have to be on a stable dose for at least 4 weeks prior to randomization. Subjects on MTX must be on folic acid supplementation before randomization
  13. Subjects who are on a conventional DMARD other than MTX or sulfasalazine must discontinue the DMARD 4 weeks prior to randomization, except for leflunomide, which must be be discontinued 8 weeks prior to randomization, unless a cholestyramine washout has been performed
  14. Subjects taking systemic must be on a stable dose of ≤10 mg/day prednisone or equivalent for at least 2 weeks before randomization

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible for inclusion in this study

  1. Subjects with total ankylosis of the spine
  2. Chest x-ray or MRI with evidence of ongoing infectious or malignant process obtained within 3 months of screening and evaluated by a qualified physician
  3. Subjects taking moderate and high potency opioid analgesics (e.g. methadone, hydromorphone, morphine)
  4. Presence of significant medical problems which at investigator's discretion, will prevent the subject from participating in the study, including but not limited to the following: Subjects with severely reduced kidney function (estimated (eGFR) \<29 ml/min/1.73m2), history of renal trauma, glomerulonephritis, or patients with one kidney only, or a serum creatinine level exceeding 1.5 mg/dl (132.6 μmol/L)
  5. Any therapy by intra-articular injections (e.g. ) within 4 weeks before Randomization
  6. Underlying conditions (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy
  7. Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol
  8. Active systemic infections during the last two weeks (exception: common cold) prior to randomization or any infection that reoccurs on a regular basis
  9. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection as defined by either a positive purified protein derivative (PPD) skin test (the size of induration will be measured after 48-72 hours, and a positive result is defined as an induration of ≥ 5 mm or according to local practice/guidelines) or a positive QuantiFERON TB-Gold test as indicated in the assessment schedule in Table 8-1. Subjects with a positive test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment according to local country guidelines must have been initiated
  10. Past medical history of infection with or prior to randomization or active infection or on treatment for at randomization
  11. History of lymphoproliferative disease or any known , or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed)
  12. Use or planned use of prohibited concomitant medication (see Section 6.2.2)
  13. Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor tolerability or lack of access to veins)
  14. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  15. History or evidence of ongoing alcohol or drug abuse, within the last six months before randomization
  16. Screening total WBC count \<3,000/μl, or \<100,000/μl or neutrophils \<1,500/μl or \<8.5 g/dl (85 g/L)
  17. History of liver disease or liver injury indicated by abnormal liver function tests, such as (AST), SGPT (ALT), alkaline phosphatase and serum . The investigator should be guided by the following criteria:

    • Any single parameter may not exceed 2 x the (ULN). A single parameter elevated up to and including 2 x ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.
    • If the total bilirubin concentration is increased above 2 x ULN, total bilirubin should be differentiated into the direct and indirect reacting bilirubin. In any case, serum bilirubin should not exceed the value of 1.6 mg/dL (27 µmol/L)
  18. Significant medical problems or diseases, including but not limited to the following:

    uncontrolled hypertension (≥160/95 mmHg), congestive heart failure ( status of class III or IV), uncontrolled diabetes, or very poor functional status precluding ability to perform self-care

  19. Plans for administration of during the study period or within 6 weeks prior to randomization
  20. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during the entire study or longer if required by locally approved prescribing information (e.g., 20 weeks in EU). Effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject
    • Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps). For UK: with spermicidal foam/gel/film/cream/ vaginal suppository
    • Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception
    • Placement of an intrauterine device or intrauterine system In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

    Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential.

  21. Active ongoing inflammatory diseases other than axSpA that might confound the evaluation of the benefits of secukinumab therapy, including inflammatory bowel disease or uveitis
  22. Current severe progressive or uncontrolled disease which in the judgment of the clinical investigator renders the subject unsuitable for the trial
  23. Use of other drugs at the time of enrollment, or within 5 half- lives of enrollment, or within 4 weeks until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations
  24. History of to any of the study drug constituents
  25. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor
  26. Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
527 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Secukinumab intravenous (i.v.) regimen

    Drug: Secukinumab

  • Placebo comparator
    Placebo

    Placebo intravenous (i.v.) regimen

    Drug: Placebo

Interventions

  • The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)

    Also known as: AIN457

  • DrugPlacebo

    The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an ASAS40 (Assessment of SpondyloArthritis International Society Criteria)

    ASAS40 is ≥ 40% and an absolute improvement from baseline of ≥20 units (range 0-100) in ≥ 3 of the following 4 domains: back pain \[10 cm visual analogue scale (VAS)\], patient global assessment of disease activity (10 cm VAS), physical function (BASFI; range 0-100) and inflammation (mean score of items 5 and 6 of the BASDAI; both 10 cm VAS) without any worsening in the remaining domain. ASAS consists of 6 domains (4 main and 2 additional): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the BAS Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the BAS Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Major Improvement

    ASDAS-CRP was utilized to assess disease activity status. Parameters used for the ASDAS included: total back pain (BASDAI question 2), patient's global assessment of disease activity, peripheral pain/swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6) and CRP in mg/L. Disease activity states: inactive disease, moderate disease activity, high disease activity, and very high disease activity. The three values selected to separate these states are: \< 1.3 between inactive disease and moderate disease activity; \< 2.1 between moderate disease activity and high disease activity; and \> 3.5 between high disease activity and very high disease activity. Selected cutoffs for improvement scores are a change of ≥ 1.1 unit for "minimal clinically important improvement" and a change of ≥ 2.0 units for "major improvement" .

    Time frame: Baseline to Week 16

  2. The Change From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    BASDAI consists of a 0 through 10 scale (0 indicating no problem and 10 indicating the worst problem, captured as a continuous VAS), which was used to answer six questions pertaining to the five major symptoms of AS: fatigue, spinal pain, peripheral joint pain / swelling,, areas of localized tenderness (enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity. To give each symptom equal weight, the mean of the two scores relating to morning stiffness is taken into account (questions 5 and 6). The resulting 0 to 10 score is added to the scores for questions 1 through 4. The resulting 0 to 50 score is divided by 5 to give a final 0 10 BASDAI score.

    Time frame: Baseline to Week 16

  3. Percentage of Participants Who Achieved an ASAS 5/6 (Assessment of Spondylarthritis International Society Criteria)

    The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains. A higher score on the VAS signifies higher severity. ASAS consists of 6 domains (4 main and 2 additional): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the BAS Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the BAS Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).

    Time frame: Baseline to Week 16

  4. The Change From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI)

    The BASFI is a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The questions were chosen on the basis of predominant input from subjects with AS. The first eight questions consider activities related to functional anatomy. The final two questions assess the subjects' ability to cope with everyday life. A 0-10 scale (captured as a continuous VAS) is used to answer the questions. The BASFI score is the mean of the ten scales - a value between 0 and 10.

    Time frame: Baseline to Week 16

  5. The Change From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS)

    The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The eight domains are based on a scale from 0-100 while PCS and MCS are norm-based scores with a mean of 50 and a standard deviation of 10. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline to Week 16

  6. The Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQol)

    The ASQoL is a self-administered questionnaire designed to assess health-related quality of life in adult subjects with AS. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response, resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower scores indicate better quality of life. Items include an assessment of mobility/energy, self care and mood/emotion. The recall period is "at the moment".

    Time frame: Baseline to Week 16

  7. The Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP)

    This assessment (laboratory assessment) was performed in order to identify the presence of inflammation, to determine its severity and to monitor the response to treatment. Exponentially transformed LSM, the geometric mean ratio of post-baseline/baseline. A value \<1 indicates a reduced CRP

    Time frame: Baseline to Week 16

  8. Percentage of Participants Who Achieved an ASAS20 (Assessment of SpondyloArthritis International Society Criteria)

    The ASAS Response Criteria (ASAS20) is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the VAS signifies higher severity. ASAS consists of 6 domains (4 main and 2 additional): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the BAS Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the BAS Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).

    Time frame: Baseline to Week 16

  9. The Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease.

    ASDAS-CRP was utilized to assess disease activity status. Parameters used for the ASDAS included: total back pain (BASDAI question 2), patient's global assessment of disease activity, peripheral pain/swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6) and CRP in mg/L. Disease activity states: inactive disease, moderate disease activity, high disease activity, and very high disease activity. The three values selected to separate these states are: \< 1.3 between inactive disease and moderate disease activity; \< 2.1 between moderate disease activity and high disease activity; and \> 3.5 between high disease activity and very high disease activity. Selected cutoffs for improvement scores are a change of ≥ 1.1 unit for "minimal clinically important improvement" and a change of ≥ 2.0 units for "major improvement"

    Time frame: Baseline to Week 16

  10. Percentage of Participants Who Achieved ASAS20 (Assessment of Spondylarthritis International Society Criteria) Partial Remission.

    ASAS partial remission criteria are defined as a value not above 2 units in each of the four main ASAS domains on a scale of 0-10. ASAS consists of 6 domains (4 main and 2 additional): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the BAS Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the BAS Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).

    Time frame: Baseline to Week 16

  11. Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Consisting of 19 items, the PSQI measures several different aspects of sleep, offering seven component scores and one composite score. The component scores consist of subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denoted a healthier sleep quality.

    Time frame: Baseline to Week 16

07

Results

Posted Jan 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
Started264262
Completed period 1255253
Started period 2255251
Completed period 2233235
Completed227233
Not completed3729
Withdrew: Adverse event - tp 152
Withdrew: Lost to follow-up tp 111
Withdrew: Progressive disease - tp 101
Withdrew: Subject decision - tp 135
Withdrew: Adverse event - tp 256
Withdrew: Death - tp 210
Withdrew: Lost to follow-up - tp 252
Withdrew: Physician decision - tp 242
Withdrew: Pregnancy - tp 211
Withdrew: Subject decision - tp 2119
Withdrew: New therapy for study indication - tp 210

Outcome measures

PrimaryPercentage of Participants Who Achieved an ASAS40 (Assessment of SpondyloArthritis International Society Criteria)

ASAS40 is ≥ 40% and an absolute improvement from baseline of ≥20 units (range 0-100) in ≥ 3 of the following 4 domains: back pain \[10 cm visual analogue scale (VAS)\], patient global assessment of disease activity (10 cm VAS), physical function (BASFI; range 0-100) and inflammation (mean score of items 5 and 6 of the BASDAI; both 10 cm VAS) without any worsening in the remaining domain. ASAS consists of 6 domains (4 main and 2 additional): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the BAS Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the BAS Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ASAS40 (Assessment of SpondyloArthritis International Society Criteria)
percentage of participantsAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
Percentage of Participants Who Achieved an ASAS40 (Assessment of SpondyloArthritis International Society Criteria)40.85 (34.94 to 46.76)22.94 (17.86 to 28.02)
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Regression, Logistic · p = <0.0001 · Marginal difference: 17.91 · 95% CI 10.12 to 25.71
SecondaryPercentage of Participants Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Major Improvement

ASDAS-CRP was utilized to assess disease activity status. Parameters used for the ASDAS included: total back pain (BASDAI question 2), patient's global assessment of disease activity, peripheral pain/swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6) and CRP in mg/L. Disease activity states: inactive disease, moderate disease activity, high disease activity, and very high disease activity. The three values selected to separate these states are: \< 1.3 between inactive disease and moderate disease activity; \< 2.1 between moderate disease activity and high disease activity; and \> 3.5 between high disease activity and very high disease activity. Selected cutoffs for improvement scores are a change of ≥ 1.1 unit for "minimal clinically important improvement" and a change of ≥ 2.0 units for "major improvement" .

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Major Improvement
percentage of participantsAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
Percentage of Participants Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Major Improvement27.99 (22.86 to 33.12)7.54 (4.44 to 10.64)
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Regression, Logistic · p = <0.0001 · Marginal difference: 20.45 · 95% CI 14.45 to 26.44
SecondaryThe Change From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

BASDAI consists of a 0 through 10 scale (0 indicating no problem and 10 indicating the worst problem, captured as a continuous VAS), which was used to answer six questions pertaining to the five major symptoms of AS: fatigue, spinal pain, peripheral joint pain / swelling,, areas of localized tenderness (enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity. To give each symptom equal weight, the mean of the two scores relating to morning stiffness is taken into account (questions 5 and 6). The resulting 0 to 10 score is added to the scores for questions 1 through 4. The resulting 0 to 50 score is divided by 5 to give a final 0 10 BASDAI score.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · scores on a scale
The Change From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
scores on a scaleAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
The Change From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)-2.70 ± 0.144-1.69 ± 0.144
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Mixed Models Analysis · p = <0.0001 · Ls mean change: -1.01 · 95% CI -1.38 to -0.64
SecondaryPercentage of Participants Who Achieved an ASAS 5/6 (Assessment of Spondylarthritis International Society Criteria)

The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains. A higher score on the VAS signifies higher severity. ASAS consists of 6 domains (4 main and 2 additional): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the BAS Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the BAS Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of participaants
Percentage of Participants Who Achieved an ASAS 5/6 (Assessment of Spondylarthritis International Society Criteria)
Percentage of participaantsAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
Percentage of Participants Who Achieved an ASAS 5/6 (Assessment of Spondylarthritis International Society Criteria)43.92 (37.94 to 49.90)21.77 (16.77 to 26.77)
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Regression, Logistic · p = <0.0001 · Marginal difference: 22.15 · 95% CI 14.36 to 29.95
SecondaryThe Change From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI)

The BASFI is a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The questions were chosen on the basis of predominant input from subjects with AS. The first eight questions consider activities related to functional anatomy. The final two questions assess the subjects' ability to cope with everyday life. A 0-10 scale (captured as a continuous VAS) is used to answer the questions. The BASFI score is the mean of the ten scales - a value between 0 and 10.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · scores on a scale
The Change From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI)
scores on a scaleAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
The Change From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI)-2.33 ± 0.147-1.39 ± 0.148
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Mixed Models Analysis · p = <0.0001 · Ls mean change: -0.94 · 95% CI -1.33 to -0.56
SecondaryThe Change From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS)

The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The eight domains are based on a scale from 0-100 while PCS and MCS are norm-based scores with a mean of 50 and a standard deviation of 10. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · scores on a scale
The Change From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS)
scores on a scaleAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
The Change From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS)7.70 ± 0.4734.69 ± 0.473
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Mixed Models Analysis · p = <0.0001 · Ls mean change: 3.01 · 95% CI 1.80 to 4.22
SecondaryThe Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQol)

The ASQoL is a self-administered questionnaire designed to assess health-related quality of life in adult subjects with AS. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response, resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower scores indicate better quality of life. Items include an assessment of mobility/energy, self care and mood/emotion. The recall period is "at the moment".

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · scores on a scale
The Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQol)
scores on a scaleAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
The Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQol)-4.65 ± 0.291-2.88 ± 0.290
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Mixed Models Analysis · p = <0.0001 · Ls mean change: -1.77 · 95% CI -2.51 to -1.04
SecondaryThe Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP)

This assessment (laboratory assessment) was performed in order to identify the presence of inflammation, to determine its severity and to monitor the response to treatment. Exponentially transformed LSM, the geometric mean ratio of post-baseline/baseline. A value \<1 indicates a reduced CRP

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · ratio
The Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP)
ratioAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
The Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP)0.39 ± 1.0630.89 ± 1.062
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Mixed Models Analysis · p = <0.0001 · Relative ls mean change: 0.44 · 95% CI 0.37 to 0.51
SecondaryPercentage of Participants Who Achieved an ASAS20 (Assessment of SpondyloArthritis International Society Criteria)

The ASAS Response Criteria (ASAS20) is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the VAS signifies higher severity. ASAS consists of 6 domains (4 main and 2 additional): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the BAS Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the BAS Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ASAS20 (Assessment of SpondyloArthritis International Society Criteria)
percentage of participantsAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
Percentage of Participants Who Achieved an ASAS20 (Assessment of SpondyloArthritis International Society Criteria)63.94 (58.19 to 69.70)40.53 (34.62 to 46.44)
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Regression, Logistic · p = <0.0001 · Marginal difference: 23.41 · 95% CI 15.61 to 31.66
SecondaryThe Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease.

ASDAS-CRP was utilized to assess disease activity status. Parameters used for the ASDAS included: total back pain (BASDAI question 2), patient's global assessment of disease activity, peripheral pain/swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6) and CRP in mg/L. Disease activity states: inactive disease, moderate disease activity, high disease activity, and very high disease activity. The three values selected to separate these states are: \< 1.3 between inactive disease and moderate disease activity; \< 2.1 between moderate disease activity and high disease activity; and \> 3.5 between high disease activity and very high disease activity. Selected cutoffs for improvement scores are a change of ≥ 1.1 unit for "minimal clinically important improvement" and a change of ≥ 2.0 units for "major improvement"

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
The Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease.
percentage of participantsAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
The Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease.15.66 (11.53 to 19.78)3.08 (1.00 to 5.15)
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Regression, Logistic · p = <0.0001 · Marginal difference: 12.58 · 95% CI 7.96 to 17.19
SecondaryPercentage of Participants Who Achieved ASAS20 (Assessment of Spondylarthritis International Society Criteria) Partial Remission.

ASAS partial remission criteria are defined as a value not above 2 units in each of the four main ASAS domains on a scale of 0-10. ASAS consists of 6 domains (4 main and 2 additional): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the BAS Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the BAS Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant).

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ASAS20 (Assessment of Spondylarthritis International Society Criteria) Partial Remission.
percentage of participantsAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
Percentage of Participants Who Achieved ASAS20 (Assessment of Spondylarthritis International Society Criteria) Partial Remission.14.76 (10.49 to 19.03)4.20 (1.77 to 6.63)
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Regression, Logistic · p = <0.0001 · Marginal difference: 10.56 · 95% CI 5.64 to 15.47
SecondaryChange From Baseline in Pittsburgh Sleep Quality Index (PSQI)

The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Consisting of 19 items, the PSQI measures several different aspects of sleep, offering seven component scores and one composite score. The component scores consist of subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denoted a healthier sleep quality.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)
scores on a scaleAIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)-2.42 ± 0.222-1.76 ± 0.221
Statistical analysis
  • AIN457 6 mg/kg - 3 mg/kg i.v. vs Placebo - AIN457 3 mg/kg i.v. · Regression, Logistic · p = 0.0234 · Ls mean change: -0.66 · 95% CI -1.24 to -0.09

Adverse events

Collected over Adverse events were reported for a maximum of 478 days for participants on AIN457 (including placebo switchers) and 182 days for participants on placebo which includes the 84 days in safety follow up.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any AIN4571/517 (0.2%)32/517 (6.2%)172/517 (33.3%)
Placebo Until Week 160/261 (0%)3/261 (1.1%)35/261 (13.4%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventAny AIN457Placebo Until Week 16
Myocardial infarctionCardiac disorders2/5170/261
Abdominal painGastrointestinal disorders2/5170/261
Colitis ulcerativeGastrointestinal disorders2/5170/261
CellulitisInfections and infestations2/5170/261
CholecystitisHepatobiliary disorders0/5171/261
TonsillitisInfections and infestations0/5171/261
Stab woundInjury, poisoning and procedural complications0/5171/261
Ovarian cyst rupturedReproductive system and breast disorders0/5171/261
AnaemiaBlood and lymphatic system disorders1/5170/261
Acute left ventricular failureCardiac disorders1/5170/261
Most frequent other events
Most frequent other events
EventAny AIN457Placebo Until Week 16
COVID-19Infections and infestations65/51710/261
NasopharyngitisInfections and infestations32/5177/261
Upper respiratory tract infectionInfections and infestations22/5176/261
ArthralgiaMusculoskeletal and connective tissue disorders20/5171/261
DiarrhoeaGastrointestinal disorders18/5175/261
HeadacheNervous system disorders17/5179/261
PharyngitisInfections and infestations13/5171/261
NauseaGastrointestinal disorders12/5172/261
RhinitisInfections and infestations11/5172/261
Urinary tract infectionInfections and infestations11/5171/261

Baseline characteristics

Age, Customized
Age, Customized(Participants)AIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.Total
< 65 years253257510
65 - 75 years8412
>= 75 years314
Sex: Female, Male
Sex: Female, Male(Participants)AIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.Total
Female9984183
Male165178343
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.Total
White180179359
Black or African American7613
Asian5947106
American Indian or Alaska Native172542
Multiple156
Disease condition
Disease condition(Participants)AIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.Total
Ankylosing spondylitis208205413
Non-radiographic axial spondylarthritis5657113
Weight
Weight(kg)AIN457 6 mg/kg - 3 mg/kg i.v.Placebo - AIN457 3 mg/kg i.v.Total
Mean77.61 ± 18.00678.08 ± 18.44477.85 ± 18.210
08

Study locations

103 sites
  • Novartis Investigative Site
    Irvine, California 92604, United States
  • Novartis Investigative Site
    La Mesa, California 91942, United States
  • Novartis Investigative Site
    San Leandro, California 94578, United States
  • Novartis Investigative Site
    Upland, California 91786, United States
  • Novartis Investigative Site
    Ocoee, Florida 34761, United States
  • Novartis Investigative Site
    Plantation, Florida 33324, United States
  • Novartis Investigative Site
    Winter Park, Florida 32789, United States
  • Novartis Investigative Site
    Bowling Green, Kentucky 42101, United States
  • Novartis Investigative Site
    Cumberland, Maryland 21740, United States
  • Novartis Investigative Site
    Grand Blanc, Michigan 48439, United States
  • Novartis Investigative Site
    Lincoln, Nebraska 68516, United States
  • Novartis Investigative Site
    Potsdam, New York 13676, United States
  • Novartis Investigative Site
    Greensboro, North Carolina 27408, United States
  • Novartis Investigative Site
    Middleburg Heights, Ohio 44130, United States
  • Novartis Investigative Site
    Portland, Oregon 97239, United States
  • Novartis Investigative Site
    Duncansville, Pennsylvania 16635, United States
  • Novartis Investigative Site
    Columbia, South Carolina 29204, United States
  • Novartis Investigative Site
    Jackson, Tennessee 38305, United States
  • Novartis Investigative Site
    Memphis, Tennessee 38119, United States
  • Novartis Investigative Site
    Katy, Texas 77494, United States
  • Novartis Investigative Site
    Spring, Texas 77382, United States
  • Novartis Investigative Site
    The Woodlands, Texas 77380, United States
  • Novartis Investigative Site
    Everett, Washington 98208, United States
  • Novartis Investigative Site
    Spokane, Washington 99204, United States
  • Novartis Investigative Site
    Beckley, West Virginia 25801, United States
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Salvador, BA 40150 150, Brazil
  • Novartis Investigative Site
    Vitoria, ES 29055 450, Brazil
  • Novartis Investigative Site
    Juiz de Fora, MG 36010 570, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01244-030, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, 20241-180, Brazil
  • Novartis Investigative Site
    Sao Jose do Rio Preto, 15090 000, Brazil
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4000, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1413, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Barranquilla, Atlantico 080002, Colombia
  • Novartis Investigative Site
    Bucaramanga, Santander 0001, Colombia
  • Novartis Investigative Site
    Ibague, Tolima 730006, Colombia
  • Novartis Investigative Site
    Barranquilla, 080020, Colombia
  • Novartis Investigative Site
    Bogota, 110221, Colombia
  • Novartis Investigative Site
    Cundinamarca, 111121, Colombia
  • Novartis Investigative Site
    Ostrava, Czech Republic 772 00, Czechia
  • Novartis Investigative Site
    Praha 2, 128 50, Czechia
  • Novartis Investigative Site
    Praha 4, 140 59, Czechia
  • Novartis Investigative Site
    Praha 5, 150 06, Czechia
  • Novartis Investigative Site
    Uherske Hradiste, 686 01, Czechia
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Patra, 26443, Greece
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Guatemala City, 01011, Guatemala
  • Novartis Investigative Site
    Guatemala, 01009, Guatemala
  • Novartis Investigative Site
    Guatemala, 01010, Guatemala
  • Novartis Investigative Site
    Surat, Gujarat 395009, India
  • Novartis Investigative Site
    Bangalore, Karnataka 560 079, India
  • Novartis Investigative Site
    Mumbai, Maharashtra 400 053, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422 101, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500082, India
  • Novartis Investigative Site
    New Delhi, 110029, India
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Verona, VR 37134, Italy
  • Novartis Investigative Site
    Gwangju, 61469, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 04763, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 05030, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 05278, Korea, Republic of
  • Novartis Investigative Site
    Seremban, Negeri Sembilan 70300, Malaysia
  • Novartis Investigative Site
    Ipoh, Perak 30450, Malaysia
  • Novartis Investigative Site
    Kuching, Sarawak 93586, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Selangor Darul Ehsan, 68100, Malaysia
  • Novartis Investigative Site
    Lipa City, Batangas 4217, Philippines
  • Novartis Investigative Site
    Dasmarinas, Cavite 4114, Philippines
  • Novartis Investigative Site
    Manila, 1008, Philippines
  • Novartis Investigative Site
    Quezon, 1102, Philippines
  • Novartis Investigative Site
    Bialystok, 15-351, Poland
  • Novartis Investigative Site
    Krakow, 30 002, Poland
  • Novartis Investigative Site
    Sochaczew, 96-500, Poland
  • Novartis Investigative Site
    Torun, 87-100, Poland
  • Novartis Investigative Site
    Warszawa, 02 637, Poland
  • Novartis Investigative Site
    Chelyabinsk, 454076, Russian Federation
  • Novartis Investigative Site
    Ekaterinburg, 620137, Russian Federation
  • Novartis Investigative Site
    Kazan, 420064, Russian Federation
  • Novartis Investigative Site
    Kemerovo, 650029, Russian Federation
  • Novartis Investigative Site
    Kemerovo, 650070, Russian Federation
  • Novartis Investigative Site
    Moscow, 115522, Russian Federation
  • Novartis Investigative Site
    Novosibirsk, 630047, Russian Federation
  • Novartis Investigative Site
    Novosibirsk, 630099, Russian Federation
  • Novartis Investigative Site
    Petrozavodsk, 185019, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 197341, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 190068, Russian Federation
  • Novartis Investigative Site
    Ulyanovsk, 432063, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150003, Russian Federation
  • Novartis Investigative Site
    Danderyd, 182 88, Sweden
  • Novartis Investigative Site
    Stockholm, 171 76, Sweden
  • Novartis Investigative Site
    Bangkoknoi, Bangkok 10700, Thailand
  • Novartis Investigative Site
    Songkhla, Hat Yai 90110, Thailand
  • Novartis Investigative Site
    Khon Kaen, THA 40002, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand

Showing the first 100 of 103 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Feb 2022, 26 months.

Results were first posted in Jan 2024, 1 year 11 months after primary completion. A results delay was requested in Oct 2022.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 26 months is above that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2019
First posted
Nov 7, 2019
StartActual
Dec 11, 2019
Primary completionActual
Feb 17, 2022
CompletionActual
Dec 20, 2022
Results delay requested
Oct 14, 2022
Results first posted
Jan 23, 2024
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04156620
Responsible party
Sponsor
First posted
Nov 7, 2019
Start date
Dec 11, 2019
Primary completion
Feb 17, 2022
Completion
Dec 20, 2022
Results posted
Jan 23, 2024
Last update
Jun 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion